ga naar hoofdinhoud
Informatie voor zorgverleners Behandelprotocollen Acute myeloïde leukemie (AML) Richtlijnen en literatuur

Richtlijnen

Klik HIER voor de richtlijn 'Acute myeloïde leukemie' van de HOVON Leukemie werkgroep.

Klik HIER voor het consensus document MRD bij AML (2018) van de ELN MRD werkgroep.

Klik HIER voor het consensus document MRD bij AML (2021) van de ELN MRD werkgroep.

Literatuur

  1. Arber DA et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical and genomic data. Blood 2022; 140(11):1200-1228
  2. Pratz et al. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALA-A. Am J Hematol. 2022 Nov; 97(11):E416-E419
  3. Döhner et al. Diagnosis and management of AML in adults: 2022 recommen­dations from an international expert panel on behalf of the ELN. Blood 2022; 140(12):1345-1377 
  4. Schuurhuis GJ et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018; 131(12):1275-1291
  5. Heuser M et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2021; 138(26): 2753-2767
  6. Terwijn M et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013; 31(31): 3889-3897
  7. Zeijlemaker W et al. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia. Leukemia 2016; 30(3):708-715
  8. Ivey A et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016 Feb; 374(5):422-33
  9. Ehinger M et al. Measurable residual disease testing for personalized treatment of acute myeloid leukemia. APMIS 2019 May; 127(5)337-351
  10. Wang Y et al. In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. Blood 2014; 124(12):1880-1886
  11. Döhner H et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129:424-447
  12. Sorror ML et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106: 2912-2919
  13. Tettero JM et al. Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry. Cytometry B Clin Cytom. 2023 Nov; 104(6):426-439
  14. Versluis J et al. Risk stratification in older intensively treated patients with AML. J Clin Oncol. 42:4084-4094
  15. Lachowiez CA et al. Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML. Blood 2024; 144(26):2788-2792
  16. Lachowiez CA et al. Risk prognostication after hypomethylating agents combined with venetoclax in AML: the PRISM risk model. J Clin Oncol 2026; DOI: 10.1200/JCO-26-00347

 

Ga terug naar de AML homepage of lees meer over AML:

Ga terug naar de algemene homepage Behandelprotocollen.